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Psoralea  corylifolia  (P.  corylifolia)  is a medicinal  plant  used  primarily  in herbal  dietary  sup-
plements to  treat  skin  diseases,  such  as vitiligo  and  psoriasis.  Case  reports  of  liver  toxicity
have recently  emerged  from  its use,  which  often  includes  co-administration  with  other
herbal  products.  In this  study,  CYP3A4  inhibition  and  hepatotoxicity  of  P.  corylifolia  and
its major  components  were  evaluated  in  human  recombinant  CYP3A4  enzyme,  differen-
tiated  human  hepatoma  HuH-7  and  HepaRG  cells.  LC/MS-TOF  was  used  to identify  the
major  components  of P.  corylifolia  fruit  methanol–water  extract.  P.  corylifolia  and  its major
bioactive components  psoralen  and  isopsoralen  were  then  incubated  with  human  recom-
binant CYP3A4  (10  min)  or  differentiated  HuH-7  and HepaRG  cells (24  h)  prior  to  CYP3A4
activity  and  cytotoxicity  assays.  P.  corylifolia  extract,  psoralen,  and isopsoralen  concentra-
tion dependently  inhibited  CYP3A4  activity  with  different  potency  in  the  three  in vitroIsopsoralen
Human recombinant CYP3A4
HuH-7 cells
HepaRG cells
systems.  No  cytotoxicity  was  observed  at any  concentration  tested.  In  vitro  CYP3A4  inhibi-
tion by  P.  corylifolia  and  its major  components  suggests  potential  drug–dietary  supplement
interactions  that  warrant  further  investigations  in vivo.
Published  by  Elsevier  Ireland  Ltd. This  is  an  open  access  article  under  the CC  BY-NC-NDCYP3A4 inhibition
Hepatotoxicity
1. Introduction
The medicinal plant Psoralea corylifolia (P. corylifolia;
Babchi) is widely distributed and used as a natural alter-
native remedy due to its diverse bioactivities, including
hepatoprotective, estrogenic, antidepressant, antimicro-
bial, antioxidant, and antitumor effects [1]. However, a few
case reports have shown hepatotoxicity associated with P.
corylifolia administration. In one case study, a 44-year-old
female ingested P. corylifolia seeds every 1 h for 7 weeks
for treating osteoporosis and developed acute cholestatic
hepatitis [2]. In another case study, a 64-year-old female
∗ Corresponding author. Tel.: +1 240 402 3408.
E-mail address: yitong.liu@fda.hhs.gov (Y. Liu).
http://dx.doi.org/10.1016/j.toxrep.2015.03.006
2214-7500/Published by Elsevier Ireland Ltd. This is an open access article u
by-nc-nd/4.0/).license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
developed severe hepatotoxicity after 9 months admin-
istration of three kinds of herbal tablets and an herbal
tea for treating vitiligo. Tablets made from P. corylifolia
leaves were identiﬁed as the most probable cause of the
liver toxicity [3]. Furthermore, there were three cases of
liver injury, including acute hepatitis, jaundice or abnor-
mal  liver biochemistry, associated with consumption of
P. corylifolia dried seeds (Fructus psoraleae) in the Chinese
population [4]. Psoralen and isopsoralen are the two major
furocoumarins in P. corylifolia. Psoralen plus UVA (PUVA)
therapy has been used to treat skin diseases, such as vitiligo
and psoriasis [5]. Long-term psoralen or isopsoralen usage
has been associated with hepatotoxicity in mice and rats
[6,7]. However, the underlying hepatotoxic mechanisms of
P. corylifolia and its major components are not well eluci-
dated.
nder the CC BY-NC-ND license (http://creativecommons.org/licenses/
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Cytochrome P450 3A4 (CYP3A4) is the most abundant
iver and intestine metabolic enzyme, and it plays a key
ole in the detoxiﬁcation and bioactivation of drugs and
erbal dietary supplements [8]. CYP3A4 mediated liver
oxicity together with drug–drug and drug–dietary supple-
ent interactions are major concerns in drug development
nd consumer safety [9]. Although CYP3A4 inhibition or
nduction does not directly cause hepatotoxicity, the sub-
equent interactions of co-administered substances could
ead to over-dose and toxicity such as that reported for St.
ohn’s wort [10]. Subcellular fractions like human recom-
inant enzyme and microsomes lack an intact cellular
ystem and often overestimate CYP3A4 inhibition [11].
herefore, primary human hepatocytes or metabolically
ompetent hepatoma cell lines, such as dimethyl sulfoxide
DMSO) treated HuH-7 cells [12] and HepaRG cells [13],
erve as additional tools for investigating CYP3A4 activ-
ty in vitro. DMSO-treated HuH-7 cells express hepatocyte
ifferentiation marker genes, elevated cytochrome P450s
nd glucuronosyltransferases [12], making them a valuable
odel for in vitro enzyme inhibition and hepatotoxicity
tudies. HepaRG cells express comparable or higher lev-
ls of metabolic enzymes, especially CYP3A4, compared to
rimary human hepatocytes [14,15].
In this study, CYP3A4 inhibition and hepatotoxicity
f P. corylifolia,  and its bioactive components psoralen
nd isopsoralen, were investigated using human recombi-
ant CYP3A4 enzyme, DMSO-treated HuH-7 and HepaRG
ells. Troleandomycin, a potent CYP3A4 mechanism-based
nhibitor [8], was used as a positive control in the in vitro
ystems.
. Materials and methods
.1. Materials
Human hepatoma HuH-7 cells were obtained from
ealth Science Research Resources Bank, Japan Health
ciences Foundation (Osaka, Japan). HepaRG cells were
urchased from Life Technologies (Grand Island, NY). Cell
ulture medium and medium supplements were pur-
hased from Life Technologies (Grand Island, NY). Fetal
ovine serum was purchased from Atlanta Biologicals
Lawrenceville, GA). The following compounds (all ≥97%
urity) were obtained from Sigma–Aldrich (St. Louis, MO):
sopsoralen, DMSO, troleandomycin, methanol, acetoni-
rile, water, and formic acid. P450-Glo CYP3A4 assay
luciferin-IPA) and CellTiter-Fluor cell viability assays
ere purchased from Promega (Madison, WI). Supersomes
uman CYP3A4 plus reductase and b5, NADPH regenera-
ing system, and rat tail collagen type I were obtained from
orning (Corning, NY). Authenticated P. corylifolia fruit was
urchased from American Herbal Pharmacopoeia (Scotts
alley, CA). Psoralen (≥98%) was obtained from Enzo Life
ciences (Farmingdale, NY).
.2. Preparation of P. corylifolia fruit extractP. corylifolia fruit was ground to a ﬁne powder using
 pestle and mortar. The powder was extracted with
0 mL  methanol–water (1:1) per gram. The mixture wasorts 2 (2015) 530–534 531
sonicated in a water bath for 30 min  at room temperature
followed by centrifugation at 1000 × g for 5 min. The super-
natant was ﬁltered through a 0.45 m ﬁlter into a glass vial,
and solvent was  removed using a SpeedVac evaporator. Dry
samples were stored at 4 ◦C protected from light.
2.3. LC/MS-TOF identiﬁcation of major components of P.
corylifolia fruit extract
P. corylifolia fruit extract was dissolved to a ﬁnal con-
centration of 100 g/mL in acetonitrile–water (5:95). Com-
pounds were separated on a 50 mm × 3.0 mm (2.7-micron)
Poroshell 120 EC-C18 column (Agilent Technologies, Santa
Clara, CA) eluted with a 9 min  gradient of 30–98% of solvent
B at a ﬂow rate of 0.5 mL/min. Solvent A was composed of
0.1% formic acid in water; while solvent B was  composed of
0.1% formic acid in acetonitrile. Column efﬂuent was  ana-
lyzed in a 6520B QTOF hybrid mass spectrometer (Agilent
Technologies, Santa Clara, CA). Data were collected in pos-
itive ESI mode. For MS/MS, collision cell energy was set to
a constant 20 eV. Molecular features were identiﬁed from
total ion chromatograms (TIC) using Agilent Mass Hunter
software. Compounds were tentatively identiﬁed by exact
mass using both published data sources and the Agilent
personal Metlin database with a mass error tolerance of
10 ppm.
2.4. Cell culture
HuH-7 cells were cultured in Dulbecco’s minimal essen-
tial medium (DMEM) (low glucose, pyruvate, GlutaMax),
supplemented with MEM  non-essential amino acids (1%),
HEPES (10 mM)  and fetal bovine serum (10%). HuH-7 cells
were plated (6 × 104 cells/cm2) in the 96-well tissue cul-
ture plates pre-coated with rat tail collagen type I. HuH-7
cells were ﬁrst cultured to conﬂuence (1 week), and then
treated with 1% DMSO (2 weeks) before use.
HepaRG cells were grown according to the supplier’s
protocol, and seeded in 96-well plates (3 × 105 cells/cm2)
pre-coated with rat tail collagen type I. Four hours after
plating, HepaRG cells were used for CYP3A4 inhibition and
hepatotoxicity studies.
2.5. Measurement of CYP3A4 inhibition
For cell-based studies, DMSO-treated HuH-7 and
HepaRG cells were incubated with P. corylifolia extract
(0.5–100 g/mL), psoralen (1–200 M),  isopsoralen
(1–200 M)  or troleandomycin (1–100 M)  at 37 ◦C for
24 h. Before CYP3A4 activity measurement, treatments
were removed, and cells were washed to minimize poten-
tial interference from treatment solutions. CYP3A4 activity
was determined by incubation with luciferin-IPA (3 M;
Km value) for 30 or 60 min. The reaction was terminated
by addition of luciferin detection reagent, followed by
luminescence measurement.
For human recombinant CYP3A4 enzyme inhibition
studies, the incubation mixture (100 L) consisted of
the following: potassium phosphate buffer (0.1 M,  pH
7.4), NADPH regenerating system, human recombinant
CYP3A4 (0.1 pmol), luciferin-IPA (3 M;  Km value), and P.
logy Rep532 Y. Liu, T.J. Flynn / Toxico
corylifolia extract (0.5–80 g/mL), psoralen or isopsoralen
(1–200 M),  or troleandomycin (0.02–1 M).  The reaction
was initiated by adding human recombinant CYP3A4 and
terminated by addition of the luciferin detection reagent
after a 10 min  reaction at room temperature. Luminescence
readings of P. corylifolia extract, psoralen, isopsoralen and
troleandomycin treatments were used for background cor-
rection when calculating CYP3A4 inhibition.
2.6. Measurement of cytotoxicity
Cell viability (live-cell protease activity) of DMSO-
treated HuH-7 and HepaRG cells after CYP3A4 assay
was determined using the CellTiter-Fluor assay.
Cells were incubated with CellTiter-Fluor substrate
glycylphenylalanyl–aminoﬂuorocoumarin (GF-AFC) at
37 ◦C for 60 min  before ﬂuorescence measurement.2.7. Data analysis
SigmaPlot 8.0 (San Jose, CA) was used to ﬁt CYP3A4
inhibition data and calculate IC50 values. IC50 was the
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Fig. 1. (A) Total extracted compound chromatogram from LC/MS-TOF analysis o
putatively by retention time and exact mass except those marked by ‘*’ which we
(3)  neobavaisoﬂavone; (4) bavachin; (5) corylin; (6) bavachromene; (7) psorali
MS/MS  spectra of psoralen and isopsoralen peaks, respectively. Retention times 
not  shown).orts 2 (2015) 530–534
half-maximal inhibitory concentration of psoralen, isopso-
ralen, P. corylifolia or troleandomycin determined using a
Hill nonlinear regression model.
3. Results and discussion
3.1. LC/MS-TOF characterization
Fig. 1A displays the extracted compound LC/MS chro-
matogram of P. corylifolia fruit extract. The chromatogram
is qualitatively similar to a published LC ﬁngerprint for P.
corylifolia fruit [16], with psoralen and isopsoralen com-
prising 41% and 22% of the total peak volume, respectively.
MS/MS  analysis using authentic standards (Fig. 1B and C)
conﬁrmed the identities of psoralen and isopsoralen in the
methanol–water extract of P. corylifolia fruit.
3.2. Measurement of cytotoxicityNo signiﬁcant cytotoxicity (<15%) was observed in
DMSO-treated HuH-7 and HepaRG cells at any concentra-
tion tested after 24 h treatment.
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f Psoralea corylifolia fruit extract. Compound identiﬁcations were made
re conﬁrmed using authentic standards: (1) psoralen*; (2) isopsoralen*;
din*; (8) isobavachalcone; (9) bavachinin; (10) bavachalcone. (B and C)
and MS/MS  spectra were identical to those of authentic standards (data
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Table  1
IC50 values of CYP3A4 in different in vitro systems.
Human
recombinant
CYP3A4
DMSO-treated
HuH-7
HepaRGa
Psoralen (M)  30.8 57.7 >200
Isopsoralen (M) 36.8 29.1 >200
P. corylifolia (g/mL) 6.0 20.6 >100
Troleandomycin (M) 0.1 27.8 0.6
a Less than 30% of CYP3A4 inhibition was  observed in HepaRG cells
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Linn-Kushtanashini, Pharmacogn. Rev. 4 (2010) 69–76.or psoralen, isopsoralen or P. corylifolia up to the highest concentration
ested.
.3. Measurement of CYP3A4 inhibition
For cell-based studies, CYP3A4 activity was normal-
zed by cell viability for individual samples. Psoralen,
sopsoralen, and P. corylifolia concentration dependently
nhibited CYP3A4 activity, yielding IC50 values (Table 1)
arying within 3.5 fold between human recombinant
YP3A4 enzymes and DMSO-treated HuH-7 cells. However,
soralen, isopsoralen, or P. corylifolia inhibited less than
0% of CYP3A4 activity (data not shown) in HepaRG cells
p to the highest concentration tested.
Observed differences between human recombinant
YP3A4 enzyme, DMSO-treated HuH-7 cells, and HepaRG
ells could result from the physical-chemical proper-
ies of test substances, differential nonspeciﬁc binding,
ell membrane permeability, active transport, or involve-
ent of additional metabolic enzymes. Furthermore, it is
nown that the basal CYP3A4 activity in different cell sys-
ems ranks in the order of HepaRG cells > primary human
epatocytes > DMSO-treated HuH-7 cells [12,14]. Minimal
nhibition of CYP3A4 by psoralen, isopsoralen, and P. coryli-
olia could also result from the extensive metabolism and
fﬂux transportation in HepaRG cells, which express com-
arable or higher levels of various metabolic enzymes and
fﬂux transporters compared with primary human hepa-
ocytes [17]. These results demonstrate the value of using
ultiple in vitro systems when studying enzyme inhibition.
CYP3A4 inhibition by P. corylifolia is important because
. corylifolia is often co-administered with drugs or other
ietary supplements [7]. Once CYP3A4 is inhibited, the
etabolism of substrate drugs or dietary supplements
ould be compromised and cause over-dose or toxicity.
linical cases of P. corylifolia toxicity often involve co-
dministration of multiple herbal drugs [3]. Thus, toxicity
ttributed to P. corylifolia could arise from CYP3A4 inhi-
ition and subsequent elevated levels of co-administered
YP3A4 substrate drugs or dietary supplements. In the
urrent study, P. corylifolia fruit extract and its two  most
bundant components psoralen and isopsoralen were stud-
ed for CYP3A4 inhibition, but other components could also
ontribute to overall inhibition.
It is critical that test agent concentrations used in in vitro
tudies are relevant to in vivo exposure. A pharmacoki-
etic study of oral administration of P. corylifolia fruit
9.12 mg/kg coumarin components solution containing
1.26% psoralen and 48.13% isopsoralen) in rats reported
lasma Cmax of 135 M and 201 M for psoralen and isop-
oralen, respectively [18]. Since the concentrations used inorts 2 (2015) 530–534 533
the current study are comparable to in vivo concentrations
for psoralen and isopsoralen, our in vitro CYP3A4 inhibition
data is relevant to in vivo situations. However, it is impor-
tant to point out that potential species differences may  play
a role in the in vivo pharmacokinetics of P. corylifolia and
related compounds between lab animals and human.
The inhibitory potency of psoralen and isopsoralen was
compared to troleandomycin, a strong CYP3A4 irreversible
inhibitor in vitro [19]. Different rankings of CYP3A4 inhi-
bition potency were observed in the three in vitro systems
(Table 1). It is worth pointing out that in vitro inhibition
does not necessarily translate to in vivo CYP3A4 inhibition
because of differential absorption, efﬂux transportation,
and ﬁrst-pass metabolism, which all contribute to the pre-
systemic removal of xenobiotics. Therefore, the clinical
relevance of the current results warrants further evaluation
in vivo.
4. Conclusion
P. corylifolia and its major bioactive components pso-
ralen and isopsoralen are in vitro CYP3A4 inhibitors. Animal
and clinical interaction studies are needed for further vali-
dation. Caution may  be needed when co-administering P.
corylifolia with other herbals or drugs which are CYP3A4
substrates.
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